Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Alvesco 80 mcg Inhaler

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Ciclesonide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Ciclesonide

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

What Alvesco is: Alvesco is a clear and colorless aerosol spray for you to breathe in through your mouth and into your lungs. It is a Preventer medication (corticosteroid) that has to be taken every day and which becomes active only after it has been inhaled into your lungs. What Alvesco is used for: Alvesco is used to treat persistent asthma in adult and adolescent patients (12 years old and more). How Alvesco works: Alvesco helps you to breathe more easily by decreasing the symptoms of your asthma and by lessening the chances of an asthma attack. The effect builds up over a period of time, so this medicine needs to be taken every day, even when you are feeling well. This medicine is not suitable for use in an acute attack of breathlessness. For quick relief from such an attack, use only your Reliever inhaler. 2.

What you need to know before you take it

e Alvesco

Do not use Alvesco if you are allergic to ciclesonide or any of the other ingredients of this medicine. (listed in section 6). Warnings and precautions Talk to your doctor or pharmacist before using Alvesco. •

Before beginning treatment with this medicine, please tell your doctor if: you have ever been treated, or are currently being treated, for pulmonary tuberculosis (TB), fungal, viral or bacterial infections.

Check with your doctor if you are not sure. It is important to make sure that Alvesco is the right medicine for you.

During your treatment with Alvesco contact your doctor immediately if: • breathing becomes difficult and your symptoms, coughing, breathlessness, wheezing, tightness in the chest, increasing noises (rhonchi) or other symptoms of narrowing of the airways are getting worse. (You should use your Reliever inhaler which will normally lead quickly to an improvement.) • you are waking up at night with your symptoms. • you are not getting relief from using your Reliever inhaler. Your doctor will decide on your further treatment. Contact your doctor if you experience blurred vision or other visual disturbances. Specific patient groups Patients with severe asthma are at risk of acute asthma attacks. For such patients the doctor will carry out regular thorough asthma control checks, including a lung function test. Patients who are already taking corticosteroid tablets: Alvesco can be used to replace your tablets, or to reduce the number of tablets you need to take. Please follow your doctor's instructions carefully. This will start about a week after you begin your Alvesco inhalations. The number of tablets you take will be reduced with caution over a period of time. During this period you may sometimes suffer from a general feeling of being unwell. In spite of this, it is important to continue both with your Alvesco inhalations and with slowly reducing the number of tablets you take. If you get serious symptoms such as nausea (feeling sick), vomiting (being sick), diarrhoea or a high temperature, contact your doctor. This process may sometimes reveal minor allergies such as rhinitis (inflammation of the inside of the nose) or eczema (itchy, reddening skin). If you have changed over from tablets, you will continue for a time to be at risk of reduced adrenal function, which is related to the corticosteroid tablets you take. The symptoms of reduced adrenal function (e.g. dizziness, fainting, nausea, loss of appetite, moodiness, decrease in body hair, inability to cope with stress, weakness, headaches, memory problems, allergies, food cravings, and blood sugar disorders) may also continue for some time. You may also need to see a specialist to determine the extent of the reduction in adrenal function. Your doctor will also do regular checks on your adrenal function. During periods of stress, for example, having an operation, worsening asthma attacks, it is possible that you will need extra corticosteroid tablets. If so, you must carry a steroid warning card which says so. Patients with liver or kidney disorders There is no need to adjust the dose of ciclesonide if you have liver or kidney problems. If you suffer from a severe liver condition, your doctor will check you more carefully for possible side effects resulting from disturbance of normal steroid production. Children below 12 years of age: This medicine is not recommended for children below the age of 12 because of a lack of information about its possible effects. Other medicines and Alvesco Please inform your doctor before using Alvesco, if you are currently being treated for any fungal or viral infections with medicine containing: ketoconazole, itraconazole, ritonavir, cobicistat, nelfinavir.

These may intensify the action of Alvesco so that the probability of side effects cannot be completely ruled out and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines without a prescription. Alvesco with food and drink There is no interaction between Alvesco and food and drink. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Because there is not enough information about the effects of Alvesco on pregnant women, your doctor will discuss with you the risks and benefits of using Alvesco. Ciclesonide (the active ingredient in Alvesco) may be taken during pregnancy only when the possible benefits to the mother justify the possible risk to the developing baby. If your doctor decides that you can continue using Alvesco, the smallest possible dose of ciclesonide will be used to maintain asthma control. The adrenal function will be carefully monitored in children of mothers who received corticosteroids during pregnancy. Talk to your doctor if you want to use Alvesco during breast-feeding. It is not known whether inhaled ciclesonide passes into the breast milk in humans. Prescribing Alvesco to women who are breast feeding will therefore only be considered if the expected benefit to the mother outweighs the possible risk to the child. Driving and using machines Alvesco and its ingredients have no or negligible effects on the ability to drive or to use machinery. Alvesco contains ethanol This medicine contains 4.7 mg of alcohol (ethanol) in each dose. The amount in a dose of this medicine is equivalent to less than 1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects. 3.

How to take it

Alvesco

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. •

If you have just started to use this medicine instead of, or as well as, taking corticosteroid tablets, see section 2, Patients who are already taking corticosteroid tablets.

How much Alvesco should I take each day? Your doctor will have spoken to you about how much of your medicine you need to take each day. This will depend on your individual need. •

The recommended dose of Alvesco is 160 micrograms once daily, which leads to asthma control in the majority of patients.

•

In some patients a dose reduction to 80 micrograms, once daily, may be an adequate dose for maintaining effective control of their asthma.

•

An increased dosage of Alvesco may become necessary for a short period of time in patients who suffer a severe worsening of their asthma symptoms. This can be up to 640 micrograms per day, delivered as 320 micrograms twice daily but no data confirming the additional therapeutic effect after 3 months with these higher doses are available.

If necessary, your doctor may also prescribe corticosteroid tablets and/or, in the case of an infection, an antibiotic. Your doctor will adjust your dose to the minimum necessary to control your asthma. You should start to notice an improvement in your symptoms (wheezing, tight chest and coughing) within 24 hours. When should I use my Alvesco inhaler? In most cases, either in the morning or in the evening – as one or two puffs once a day. Follow your doctor's instructions very carefully. It is important that you take Alvesco regularly every day, even if you feel better. If you find that you have to use your Reliever inhaler more than 2-3 times a week, you should contact your doctor to have your medicine reviewed. How do I use my Alvesco inhaler? It is important that a doctor, nurse or pharmacist shows you first how to use your Alvesco inhaler properly. A good technique will make sure you are receiving the correct amount into your lungs. Please use the instructions in this leaflet as a reminder. You may wish to practice in front of the mirror for the first couple of times until you are confident that you are using your Alvesco inhaler properly. Make sure that none of your medicine is escaping from the top or sides of your mouth. If you have a new inhaler, or if you have not used your inhaler for a week or more, it must be tested before you use it. Remove the mouthpiece cover and press down three times on the canister inside the inhaler to release three puffs into the air – away from you. You do not need to shake your Alvesco inhaler before using it. The medicine is already in a very fine solution, mixed to ensure you receive the correct dose with each puff. During inhalation, you can either be sitting down or standing up. Follow these instructions carefully and use the pictures to guide you.

1. Remove the mouthpiece cover and check the mouthpiece, both the inside and the outside, to make sure that it is both clean and dry.

2.

Hold the inhaler upside down (base of the canister at the top) with your forefinger on the base of the canister and your thumb under the mouthpiece.

3.

Breathe out as far as is comfortable. Do not breathe out through the inhaler.

4.

Place the mouthpiece in your mouth and close your lips firmly around it.

5.

Just after starting to breathe in through your mouth, press down with your forefinger on the top of the inhaler to release a puff of the medicine while you are still breathing in slowly and deeply. Please take care that the puff of medicine does not escape through the top, bottom or sides of your mouth.

6.

Hold your breath, take the inhaler from your mouth and remove your finger from the top of the inhaler. Continue holding your breath for about ten seconds or as long as is comfortable. Breathe out slowly through your mouth. Do not breathe out through the inhaler.

It is important that you do not rush steps 3 to 6.

7.

If you have been instructed to take another puff, wait about half a minute and repeat steps 3 to 6.

8.

After use, always replace the mouthpiece cover to keep out dust. Replace firmly and snap into position.

9.

For hygiene reasons please clean the mouthpiece weekly with a dry tissue, both inside and out. using a dry, folded tissue, wipe over the front of the small hole where the medicine comes out. do not use water or any other liquids.

A correct technique will ensure the right amount of Alvesco is getting into your lungs every time you use your inhaler. Your doctor will check your inhalation technique regularly to ensure that your treatment can have the very best effect. When the canister is completely empty you will not feel or hear any of the propellant being discharged. If you begin to feel wheezy or tightness in the chest after using your Alvesco inhaler: • do not take any more puffs. • use your reliever inhaler to help your breathing. • contact your doctor immediately. If you find it difficult to use the inhaler, your doctor may recommend the use of a spacer. The spacer that fits the Alvesco inhaler is called AeroChamber PlusTM. If you use the AeroChamber PlusTM device, please follow the instructions provided with it. Your doctor or pharmacist will be able to advise you about the device. If you use more Alvesco than you should It is important that you take your dose as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. There is no specific treatment necessary if you have used too much Alvesco but you should inform your doctor. If high doses are used over long periods, a certain degree of reduction in adrenal function cannot be ruled out and control of the adrenal function may be necessary.

If you forget to use Alvesco If you have forgotten to use your Alvesco, just take your usual dose when it is next due. Do not take a double number of puffs to make up for the forgotten dose. If you stop using Alvesco Even if you feel better, you should not stop using your Alvesco inhaler. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. If you do stop using this medicine, you must tell your doctor immediately. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. If you notice any of the following serious side effects, stop using this medicine and talk to your doctor straight away: • severe allergic reactions such as swelling of lips, tongue and throat (may affect up to 1 in 1,000 patients treated) • allergic reactions: skin rashes, redness, itching or weals like nettle rash and hives (may affect up to 1 in 100 patients treated) • cough, or wheezing, which gets worse soon after taking an inhalation (may affect up to 1 in 100 patients treated) The other side effects seen with Alvesco are usually mild. In most cases you can continue with your treatment. The side effects you may experience are: Uncommon side effects (may affect up to 1 in 100 patients treated): • hoarseness • burning, inflammation, irritation of mouth or throat • oral thrush (oral fungal infection) • headache • bad taste • dryness of mouth or throat • nausea or vomiting Rare side effects (may affect up to 1 in 1,000 patients treated): • sensation of heartbeat (palpitations) • discomfort or pain in the abdomen • high blood pressure Frequency not known, but may also occur: • Sleeping problems, depression or feeling worried, restless, nervous, over-excited or irritable. These effects are more likely to occur in children • blurred vision Alvesco may affect the normal production of corticosteroids in your body. This is usually seen in patients taking high doses over a long period of time. These effects may include: reduced rate of growth in adolescents a thinning of the bones possible clouding of the lens of the eye (cataracts) causing blurred vision loss of vision caused by abnormally high pressure in the eye (glaucoma) moon-shaped face, weight gain in the upper body and thinning arms and legs (Cushingoid features or Cushing syndrome). Adolescents who are receiving treatment for a long period of time should have their height checked regularly by their doctor. If your growth rate is slowed, your doctor will adjust your treatment if possible to the lowest dose at which effective control of asthma is maintained.

Corticosteroid tablets can lead to more side effects than a corticosteroid inhaler such as Alvesco. If you have been taking steroid tablets before or during the use of Alvesco, the risk of side effects from the tablets may continue for a period of time. Regular check-ups with your doctor will ensure that you are taking the right dose of Alvesco for you. Regular check-ups will also identify any side effects early on and reduce the chances of them worsening. Please remember: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Alvesco Keep this medicine out of the sight and reach of children. Do not use your inhaler after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month. The container contains a pressurised liquid. Do not store above 50°C. The container should not be punctured, broken or burned even if it seems empty. As with most inhaled medicines in pressurised containers, the healing effect of this medicinal product may become smaller when the container is cold. However, Alvesco delivers the same level of dose from minus 10°C to plus 40°C. If your doctor decides to stop treatment or if the inhaler is empty, return it to your pharmacist for safe disposal. This is important as traces of medicine could remain in the container even if you have the impression that it might be empty. Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Alvesco contains The active ingredient is ciclesonide. Each actuation releases a puff (dose delivered through the mouthpiece) that contains either 80 or 160 micrograms of ciclesonide. The other ingredients are anhydrous ethanol and propellant (HFA-134a, Norflurane). This medicine contains fluorinated greenhouse gases. Alvesco 80 Inhaler, 30 puffs – Each inhaler contains 4.32 g of HFA-134a, corresponding to 0.006 tonne CO2 equivalent (global warming potential GWP = 1430). Alvesco 80 Inhaler, 60 puffs – Each inhaler contains 5.60 g of HFA-134a, corresponding to 0.008 tonne CO2 equivalent (global warming potential GWP = 1430). Alvesco 80 Inhaler, 120 puffs – Each inhaler contains 8.82 g of HFA-134a, corresponding to 0.013 tonne CO2 equivalent (global warming potential GWP = 1430). Alvesco 160 Inhaler, 30 puffs – Each inhaler contains 4.31 g of HFA-134a, corresponding to 0.006 tonne CO2 equivalent (global warming potential GWP = 1430).

Alvesco 160 Inhaler, 60 puffs – Each inhaler contains 5.59 g of HFA-134a, corresponding to 0.008 tonne CO2 equivalent (global warming potential GWP = 1430). Alvesco 160 Inhaler, 120 puffs – Each inhaler contains 8.80 g of HFA-134a, corresponding to 0.013 tonne CO2 equivalent (global warming potential GWP = 1430). What Alvesco looks like and contents of the pack Alvesco consists of a clear and colourless liquid in a pressurised aluminium container which delivers through a mouthpiece an accurately measured dose of ciclesonide in the form of a spray. Pack sizes: Inhaler with 30 accurately measured puffs. Inhaler with 60 accurately measured puffs. Inhaler with 120 accurately measured puffs. Each strength of inhaler contains enough for 30, 60 or 120 puffs. Depending on the number of puffs per day your physician has recommended you to use: • the inhaler with 30 puffs has enough medication for two to four weeks. • the inhaler with 60 puffs has enough medication for one to two months. • the inhaler with 120 puffs contains enough medication for two to four months. Not all pack sizes may be marketed in all countries. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Covis Pharma Europe B.V. Gustav Mahlerplein 2 1082MA Amsterdam The Netherlands Manufacturer Kindeva Drug Delivery Limited Derby Road, Loughborough, LE11 5SF, United Kingdom This leaflet was last revised in 03/2026.

Frequently asked questions about Alvesco 80 mcg Inhaler

How do I take Alvesco 80 mcg Inhaler?

Alvesco 80 mcg Inhaler comes as inhaler containing 80mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Alvesco 80 mcg Inhaler?

The active substance in Alvesco 80 mcg Inhaler is ciclesonide.

Are there equivalent medicines to Alvesco 80 mcg Inhaler?

Medicines with the same active substance, strength and form include: Ciclesonide Advanz Pharma 80 mcg per metered dose pressurised inhalation, solution. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Alvesco 80 mcg Inhaler, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Alvesco 80 mcg Inhaler without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Ciclesonide (4 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Alvesco is indicated in treatment to control persistent asthma in adults and adolescents (12 years and older).

4.2. Posology and method of administration

The medicinal product is for inhalation use only.

Posology

Dosing recommendation for adults and adolescents:

The recommended dose of Alvesco is 160 micrograms once daily, which leads to asthma control in the majority of patients. In patients with severe asthma and while reducing or discontinuing oral corticosteroids, a higher dose of up to 640mcg/day (given as 320mcg twice daily) may be used (see section 5.1). Patients should be given a dose of inhaled ciclesonide which is appropriate to the severity of their disease. Symptoms start to improve with Alvesco within 24 hours of treatment. Once control is achieved, the dose of Alvesco should be individualised and titrated to the minimum dose needed to maintain good asthma control. Dose reduction to 80 micrograms once daily may be an effective maintenance dose for some patients.

Alvesco should preferably be administered in the evening although morning dosing of Alvesco has also been shown to be effective. The final decision on evening or morning dosing should be left to the discretion of the physician.

Patients with severe asthma are at risk of acute attacks and should have regular assessments of their asthma control including pulmonary function tests. Increasing use of short-acting bronchodilators to relieve asthma symptoms indicates deterioration of asthma control. If patients find that short-acting relief bronchodilator treatment becomes less effective, or they need more inhalations than usual, medical attention must be sought. In this situation, patients should be reassessed and consideration given to the need for increased anti-inflammatory treatment therapy (e.g. a higher dose of Alvesco for a short period [see section 5.1] or a course of oral corticosteroids). Severe asthma exacerbations should be managed the usual way.

To address specific patient needs, such as finding it difficult to press the inhaler and breathe in at the same time, Alvesco can be used with the AeroChamber Plus spacer device.

Elderly and patients with renal or hepatic impairment

There is no need to adjust the dose in elderly patients or those with hepatic or renal impairment.

Paediatric population

The safety and efficacy of Alvesco in children aged under 12 years have not yet been established.

No sufficient data are available.

Method of administration

Precautions to be taken before handling or administering the medicinal product

The patient needs to be instructed how to use the inhaler correctly.

If the inhaler is new or has not been used for one week or more, three puffs should be released into the air. No shaking is necessary as this is a solution aerosol.

During inhalation, the patient should preferably sit or stand, and the inhaler should be held upright with the thumb on the base, below the mouthpiece.

Instruct the patient to remove the mouthpiece cover, place the inhaler into their mouth, close their lips around the mouthpiece, and breathe in slowly and deeply. While breathing in through the mouth, the top of the inhaler should be pressed down. Then, patients should remove the inhaler from their mouth, and hold their breath for about 10 seconds, or as long as is comfortable. The patient is not to breathe out into the inhaler. Finally, patients should breathe out slowly and replace the mouthpiece cover.

The mouthpiece should be cleaned with a dry tissue or cloth weekly. The inhaler should not be washed or put in water.

For instructions on use of medicinal product before administration, see section 6.6

4.3. Contraindications

Hypersensitivity to ciclesonide or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

As with all inhaled corticosteroids, Alvesco should be administered with caution in patients with active or quiescent pulmonary tuberculosis, fungal, viral or bacterial infections, and only if these patients are adequately treated.

As with all inhaled corticosteroids, Alvesco is not indicated in the treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

As with all inhaled corticosteroids, Alvesco is not designed to relieve acute asthma symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is therefore important that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Paediatric population

It is recommended that the height of children and adolescents receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.

Hepatic impairment

There is no data available in patients with severe hepatic impairment. An increased exposure in patients with severe hepatic impairment is expected and these patients should therefore be monitored for potential systemic effects.

Adrenal impairment

The benefits of inhaled ciclesonide should minimise the need for oral steroids. However, patients transferred from oral steroids remain at risk of impaired adrenal reserve for a considerable time after transferring to inhaled ciclesonide. The possibility of respective symptoms may persist for some time.

These patients may require specialised advice to determine the extent of adrenal impairment before elective procedures. The possibility of residual impaired adrenal response should always be considered in an emergency (medical or surgical) and elective situations likely to produce stress, and appropriate corticosteroid treatment considered.

For the transfer of patients being treated with oral corticosteroids:

The transfer of oral steroid-dependent patients to inhaled ciclesonide, and their subsequent management, needs special care as recovery from impaired adrenocortical function, caused by prolonged systemic steroid therapy, may take a considerable time.

Patients who have been treated with systemic steroids for long periods of time, or at a high dose, may have adrenocortical suppression. With these patients adrenocortical function should be monitored regularly and their dose of systemic steroid reduced cautiously.

After approximately a week, gradual withdrawal of the systemic steroid is started by reducing the dose by 1 mg prednisolone per week, or its equivalent. For maintenance doses of prednisolone in excess of 10 mg daily, it may be appropriate to cautiously use larger reductions in dose at weekly intervals.

Some patients feel unwell in a non-specific way during the withdrawal phase despite maintenance or even improvement of respiratory function. They should be encouraged to persevere with inhaled ciclesonide and to continue withdrawal of systemic steroid, unless there are objective signs of adrenal insufficiency.

Patients transferred from oral steroids whose adrenocortical function is still impaired should carry a steroid warning card indicating that they need supplementary systemic steroid during periods of stress, e.g. worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.

Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by systemic drug.

Paradoxical bronchospasm with an immediate increase of wheezing or other symptoms of bronchoconstriction after dosing should be treated with an inhaled short-acting bronchodilator, which usually results in quick relief. The patient should be assessed and therapy with Alvesco should only be continued, if after careful consideration the expected benefit is greater than the possible risk. Correlation between severity of asthma and general susceptibility for acute bronchial reactions should be kept in mind (see section 4.8).

Patients inhaler technique should be checked regularly to make sure that inhaler actuation is synchronised with inhaling to ensure optimum delivery to the lungs.

Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should be avoided unless the benefit outweighs the increased risk of systemic side effects of corticosteroids (see section 4.5).

This medicine contains 4.7 mg of alcohol (ethanol) in each dose. The amount in a dose of this medicine is equivalent to less than 1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects.

4.5. Interaction with other medicinal products and other forms of interaction

In vitro data indicate that CYP3A4 is the major enzyme involved in the metabolism of the active metabolite of ciclesonide M1 in man.

In a drug-drug interaction study at steady state with ciclesonide and ketoconazole as a potent CYP3A4 inhibitor, the exposure to the active metabolite M1 increased approximately 3.5‑fold, whereas the exposure to ciclesonide was not affected. Therefore, the concomitant administration of potent inhibitors of CYP 3A4 (e.g. ketoconazole, itraconazole, cobicistat-containing products, and ritonavir or nelfinavir) should be avoided unless the benefit outweighs the increased risk of systemic side effects of corticosteroids, in which case, patients should be monitored for systemic corticosteroid side-effects.

4.6. Fertility, pregnancy and lactation

Fertility and Pregnancy

There are no adequate and well-controlled studies in pregnant women.

In animal studies glucocorticoids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended inhalation doses.

As with other glucocorticoids, ciclesonide should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. The lowest effective dose of ciclesonide needed to maintain adequate asthma control should be used.

Infants born of mothers who received corticosteroids during pregnancy are to be observed carefully for hypoadrenalism.

Breast-feeding

It is unknown whether inhaled ciclesonide is excreted in human breast milk. Administration of ciclesonide to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.

4.7. Effects on ability to drive and use machines

Alvesco has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Approximately 5% of patients experienced adverse reactions in clinical trials with Alvesco given in the dose range 40 to 1280 micrograms per day. In the majority of cases, these were mild and did not require discontinuation of treatment with Alvesco.

Frequency

Uncommon

(>1/1,000, <1/100)

Rare

(1/10,000 – 1/1,000)

Unknown

System Organ Class

Cardiac Disorders

Palpitations**

Gastrointestinal Disorders

Nausea, vomiting*

Bad taste

Abdominal pain*

Dyspepsia*

General disorders and administration site conditions

Application site reactions

Application site dryness

Immune System Disorders

Angioedema

Hypersensitivity

Infections and infestations

Oral fungal infections*

Nervous System Disorders

Headache*

Psychiatric Disorders

Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural changes (predominantly in children)

Respiratory, thoracic and mediastinal disorders

Dysphonia

Cough after inhalation*

Paradoxical bronchospasm*

Skin and subcutaneous tissue disorders

Eczema and rash

Vascular disorders

Hypertension

Eye disorders

Vision, blurred (see also section 4.4)

*

**

Similar or lower incidence when compared with placebo

Palpitations were observed in clinical trials in cases mostly confounded with concomitant medication with known cardiac effects (e.g. theophylline or salbutamol).

Paradoxical bronchospasm may occur immediately after dosing and is an unspecific acute reaction to all inhaled medicinal products, which may be related to the active substance, the excipient, or evaporation cooling in the case of metered dose inhalers. In severe cases, withdrawal of Alvesco should be considered.

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma (see also section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Acute:

Inhalation by healthy volunteers of a single dose of 2880 micrograms of ciclesonide was well tolerated.

The potential for acute toxic effects following overdose of inhaled ciclesonide is low. After acute overdosage no specific treatment is necessary.

Chronic:

After prolonged administration of 1280 micrograms of ciclesonide, no clinical signs of adrenal suppression were observed. However, if higher than recommended dosage is continued over prolonged periods, some degree of adrenal suppression cannot be excluded. Monitoring of adrenal reserve may be necessary.

💬 Ask about this leaflet

Ask anything about Alvesco 80 mcg Inhaler. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →